Ibrutinib and obinutuzumab in CLL: improved MRD response rates with substantially enhanced MRD depletion for patients with > 1 year prior ibrutinib exposure
Authors
Munir, TRawstron, A
Brock, K
Vicente, S
Yates, F
Bishop, R
Cramp, S
DeTute, R
Dalal, S
Webster, N
Macdonald, D
Pettitt, A
Devereux, S
Sheehy, O
Fegan, C
Fox, C
Bloor, Adrian
Hillmen, P
Affiliation
St James’s Institute of Oncology, Leeds Teaching HospitalIssue Date
2019